$PCVX
2 catalysts touching PCVX in the last 60 days, newest first, each with the price move that followed.
- 62
Vaxcyte prices $575M convertible notes due 2032 at 1.50% interest
Vaxcyte completed a $575 million convertible debt offering at 1.50% with a 2032 maturity and $89.60 conversion price, representing a material capital raise. The conversion terms and redemption provisions are typical for convertible instruments, and near-term dilution depends on stock performance relative to the conversion price; the neutral direction reflects offsetting effects of capital access and future dilution.
PCVX ·SEC 8-K · 9 Oct 2026, 20:42 UTC - 75
Vaxcyte announces positive Phase 3 OPUS-1 topline data for VAX-31 pneumococcal vaccine
Vaxcyte reported positive topline safety, tolerability and immunogenicity results from the Phase 3 OPUS-1 pivotal trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. A successful pivotal trial readout for a late-stage vaccine program materially de-risks the development path and increases the probability of regulatory approval and market entry.
PCVX ▲SEC 8-K · 5 Oct 2026, 12:01 UTC
Information only. AURA does not give buy or sell recommendations.